AC
AMLX icon

Aldebaran Capital’s Amylyx Pharmaceuticals AMLX Stock Holding History

Aldebaran Capital’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.52M Sell
195,892
-2,000
-1% -$30.9K 2.64% 15
2026
Q1 		$2.75M Sell
197,892
-616
-0.3% -$8.66K 2.1% 19
2025
Q4 		$2.4M Sell
198,508
-5,966
-3% -$81K 2.15% 16
2025
Q3 		$2.78M Sell
204,474
-13,353
-6% -$126K 2.55% 14
2025
Q2 		$1.4M Sell
217,827
-41,426
-16% -$201K 1.38% 19
2025
Q1 		$918K Sell
259,253
-3,500
-1% -$12.5K 0.87% 23
2024
Q4 		$993K Sell
262,753
-7,050
-3% -$33.2K 0.94% 23
2024
Q3 		$874K Hold
269,803
– – 0.8% 24
2024
Q2 		$513K Buy
+269,803
New +$523K 0.48% 27

Other funds holding AMLX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Aldebaran Capital's AMLX Position: Q2 2026 in Review

Aldebaran Capital reduced its Amylyx Pharmaceuticals (AMLX) stake by 1% in Q2 2026, selling an estimated $30.9K and leaving 195,892 shares worth $3.52M. The position accounts for 2.64% of the portfolio, ranked #15.

Aldebaran Capital first reported a position in AMLX in Q2 2024 and has held it in 9 quarters since. 206 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

  • Aldebaran Capital held 195,892 shares of Amylyx Pharmaceuticals worth $3.52M as of Q2 2026.
  • Aldebaran Capital sold 2,000 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $30.9K.
  • Amylyx Pharmaceuticals made up 2.64% of Aldebaran Capital's portfolio in Q2 2026, its #15 holding.
  • Aldebaran Capital first reported a position in Amylyx Pharmaceuticals in Q2 2024 and has held it in 9 quarters since.
  • 206 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Aldebaran Capital's 13F filing for Q2 2026, filed 14 Aug 2026.